Abstract 75P
Background
We have previously shown that a large gene set can classify the tumor immune microenvironment (TIME) of patients with epithelial tumors into one of three phenotypes: immune inflamed (immune hot), immuno-suppressive (immune cold), or immune inert (immune cold). Given that the tumor is constantly evolving, identifying key genes where changes in mutation or cell signaling is associated with a change in phenotypes can lead to identification of potential new targets. Here we show three bioinformatic methodologies for this purpose.
Methods
The first approach to identifies genes hypermethylated in one phenotype and hypomethylated in another as methylation patterns can be surrogates for mutations that drive a transition across the TIME. Second, MUTECT2 annotation was used to detect high impact mutations which were associated with the phenotypes. Third, the IntAct database was used to identify potential cell signaling pairings where one gene was associated with patients classified as hot and a second gene classified patients as cold. All three of these approaches yielded genes with known targeted therapies in active clinical trials.
Results
The methylation approach identified VEGFR2 as a gene where mutations could likely affect TIME phenotypes. VEGFR2 is routinely used in clinical trials and has an approved drug on the market (ramucirumab), and mutations in VEGFR2 are seen to affect patient prognosis and drug sensitivity. With the MUTECT2 approach, mutations in STK11 were identified. Several clinical trials are examining the role that mutations in STK11 can play in altering the treatment paradigm between immunotherapy and KRAS targeted therapy. Finally, the IntAct approach identified the interaction between CRCX4 and CXCL12, known to be involved in TIME evolution and with several clinical trials being conducted designed to disrupt this interaction.
Conclusions
Utilizing a curated gene list to classify patients into TIME phenotypes and then using bioinformatic methods to find genes which may be driving transition across immune of phenotypes resulted in identifying known and well validated targets from current clinical trials. The results argue for a more careful examination of other genes that resulted from this methodology as potential targets for immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncocyte.
Disclosure
R. Seitz: Financial Interests, Personal, Advisory Role: Oncocyte, Inc. B. Ring, C. Cronister: Financial Interests, Personal, Full or part-time Employment: Oncocyte, Inc.
Resources from the same session
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
Presenter: Jelena Milovanovic
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract